Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Psychiatry›Clinical Question·Updated Jul 4, 2026·v1

first-line pharmacotherapy for major depressive disorder [Grok-4.3]

Selective serotonin reuptake inhibitors are primary pharmacologic treatments for major depressive disorder [2]. The agents carrying this designation are [[citalopram]], [[escitalopram]], [[fluoxetine]], [[fluvoxamine]], [[paroxetine]], and [[sertraline]] [2]. Guideline statements note that selective serotonin reuptake inhibitor medication possesses rigorous empirical support from randomized controlled trials and

Moderate Evidence22 references·1,064 words·5 min read·v1
Selective serotonin reuptake inhibitors are primary pharmacologic treatments for major depressive disorder [2]. The agents carrying this designation are [[citalopram]], [[escitalopram]], [[fluoxetine]], [[fluvoxamine]], [[paroxetine]], and [[sertraline]] [2].

Board Review — High Yield

  • •SSRIs listed as primary pharmacologic treatments for MDD [2]
  • •No references address the historical development or landmark trials of antidepressant pharmacotherapy.
  • •Desvenlafaxine (50-400 mg/d) retained efficacy over placebo regardless of episode duration or severity in 3647 participants [12]
  • •Evidence on pharmacotherapy is limited to desvenlafaxine trials and sertraline-olanzapine continuation in psychotic depression [11,12].
  • •Psilocybin-assisted therapy yields medium effect sizes (SMD -0.72) and higher response/remission rates than comparators through six weeks in six RCTs [16].

Deep Dive — Evidence Details

References

  1. [1]

    Walter HJ, Abright AR, Bukstein OG et al.. “Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.” Journal of the American Academy of Child and Adolescent Psychiatry (2022). PMID: 36273673 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Bousman CA, Stevenson JM, Ramsey LB et al.. “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.” Clinical pharmacology and therapeutics (2023). PMID: 37032427 ↗

    L2GUIDELINECited in: Bottom Line
  3. [3]

    Shea MT, Mete M, Green BL et al.. “Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.” The Journal of clinical psychiatry (2026). PMID: 42383820 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  4. [4]

    Zhou W, Zhang H, Jiang Y et al.. “Long-Term Effectiveness of Unguided Internet-Based Cognitive Behavioral Therapy on Major Depressive Disorder in Chinese Adults: Randomized Controlled Trial With a 12-Month Follow-Up.” JMIR mHealth and uHealth (2026). PMID: 42341343 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  5. [5]

    Veler-Poleg N, Tchizick A, Zilcha-Mano S. “Attachment Orientations and Treatment Outcomes in Psychotherapy: Does the Alliance Mediate the Association?” Clinical psychology & psychotherapy (2026). PMID: 42317130 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    de Cates AN, Hamilton S, Guru A et al.. “Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression.” Psychological medicine (2026). PMID: 42290157 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  7. [7]

    Wollmer MA, Lemke H, Waldvogel P et al.. “FaReWell Depression - a randomized controlled trial of a physiotherapeutic program for the facial rehabilitation of wellbeing in depression.” Frontiers in psychiatry (2026). PMID: 42267161 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  8. [8]

    Kang T, Zhao X, Huo X et al.. “High-Intensity Transcranial Alternating Current Stimulation for Emotion Regulation and Attentional Bias in Adolescents With Nonsuicidal Self-Injury: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42262758 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  9. [9]

    Ho NCW, Zhukovsky P, Rajji TK et al.. “Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment.” The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2026). PMID: 42203570 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Gómez Penedo JM, Peysachov G, Babl A et al.. “Predicting Heterogenous Effects of Alliance Ruptures in Depression: Implications for Personalized Psychotherapy Based on Interpersonal Functioning.” Clinical psychology & psychotherapy (2026). PMID: 42203204 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Bendel RA, Alexopoulos GS, Marino P et al.. “Effect of continuation treatment on health-related quality of life in remitted psychotic depression.” Journal of affective disorders (2026). PMID: 42176815 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Peters EM, Quadri A, Aziz S et al.. “Episode duration and severity as predictors of placebo response in major depressive disorder.” Journal of affective disorders (2026). PMID: 42176813 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  13. [13]

    Huang D, Zhang R, Lai S et al.. “Dual-Site aiTBS for Suicidal Ideation in Adolescents With Major Depressive Disorder: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42154469 ↗

    L1RCTCited in: Current Evidence and Standard
  14. [14]

    Tucciarone JM, Bandeira ID, Blasey C et al.. “Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.” The American journal of psychiatry (2026). PMID: 42151794 ↗

    L1RCTCited in: Current Evidence and Standard
  15. [15]

    Yang Y, Chen J, Yu M et al.. “Comparative efficacy of multiple non-invasive brain stimulation to treat major depressive disorder in older patients: A systematic review and network meta-analysis study based on randomized controlled trials.” Psychiatry research (2024). PMID: 39740314 ↗

    L1SR_MA_RCTCited in: On the Horizon
  16. [16]

    Menon V, Ramamurthy P, Venu S et al.. “Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.” Acta psychiatrica Scandinavica (2024). PMID: 39627679 ↗

    L1SR_MA_RCTCited in: On the Horizon
  17. [17]

    Ceolato-Martin C, Chevallier-Collins C, Clément JP et al.. “OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study).” Depression and anxiety (2024). PMID: 40226647 ↗

    L1RCTCited in: On the Horizon
  18. [18]

    Lubbers J, Geurts DEM, Spinhoven P et al.. “Rumination and Self-Compassion Moderate Mindfulness-Based Cognitive Therapy for Patients With Recurrent and Persistent Major Depressive Disorder: A Controlled Trial.” Depression and anxiety (2024). PMID: 40226644 ↗

    L1RCTCited in: On the Horizon
  19. [19]

    Yang JH, Keun Park CH, Rhee SJ et al.. “Effectiveness of internet-based cognitive behavioral therapy in reducing suicidality among high-risk patients with depression: A multicenter randomized controlled trial in Korea.” Journal of psychiatric research (2024). PMID: 39740619 ↗

    L1RCTCited in: On the Horizon
  20. [20]

    Upadhyay S, Agarwal V, Arya A et al.. “Safety and efficacy of early augmentation with Transcranial Direct Current Stimulation (tDCS) in adolescents with Major Depressive Disorder: A randomized controlled trial.” Asian journal of psychiatry (2024). PMID: 39733498 ↗

    L1RCTCited in: On the Horizon
  21. [21]

    de Leon VC, Allen RM, Quevedo J et al.. “Suicide characteristics in patients with marked treatment-resistant major depressive disorder: A RECOVER trial report.” Journal of affective disorders (2024). PMID: 39722333 ↗

    L1RCTCited in: On the Horizon
  22. [22]

    Reist C, Li P, Le Nguyen T et al.. “Safety of BI 1358894 in patients with major depressive disorder: Results and learnings from a phase II randomized decentralized clinical trial.” Clinical and translational science (2024). PMID: 39715042 ↗

    L1RCTCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…